Effect of different dosage of esketamine on bispectral index in patients with general anesthesia

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100047988

Enrollment

Unknown

Registered

2021-06-28

Start date

2021-06-29

Completion date

Unknown

Last updated

2022-04-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

perioperative brain function

Interventions

esketamine group1:Inject 0.25mg/kg esketamine intravenously under steady-state anaesthetic and surgical conditions

esketamine group2:Inject 0.5mg/kg esketamine intravenously under steady-state anaesthetic and surgical conditions

normal saline group:Inject the same volume of saline intravenously under steady-state anaesthetic and surgical conditions

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1.Aged from 18 to 65 years; 2.ASA I-II.

Exclusion criteria

Exclusion criteria: 1.BMI=28kg/m2; 2.Severe cardiovascular disease; 3.Severe hepatic or renal insufficiency; 4.Neurological or psychiatric disorders; 5.Long-term drinking.

Design outcomes

Primary

Measure	Time frame
Bispectral index;	—

Secondary

Measure	Time frame
Spectral edge frequency;Electromyography;Blood pressure;Heart rate;Regional cerebral oxygen saturation;Recovery time;Extubation time;Patient health questionnaire-9;Mini-mental state examination;Pain score;	—

Countries

China

Contacts

Public ContactWang Yanping

The First Affiliated Hospital of Zhengzhou University

282243756@qq.com+86 13526857360

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026